Navigation Links
FDA Approves Blood Thinner Brilinta for Heart Patients
Date:7/20/2011

WEDNESDAY, July 20 (HealthDay News) -- In a long-awaited move, the U.S. Food and Drug Administration late Wednesday approved the blood thinner Brilinta (ticagrelor) for use in patients with acute coronary syndromes, to help lower their odds for heart attack and death.

Acute coronary syndromes include common conditions such as unstable angina or heart attack linked to lowered blood flow to the heart, the FDA noted in a statement. Brilinta, developed by pharmaceutical giant AstraZeneca, works to prevent new blood clots from forming.

The agency's move comes after a number of studies found that Brilinta performed well against the standard blood thinner now in use, Plavix (clopidogrel).

"In clinical trials, Brilinta was more effective than Plavix in preventing heart attacks and death, but that advantage was seen with aspirin maintenance doses of 75 to 100 milligrams once daily," Dr. Norman Stockbridge, director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

In approving Brilinta, the FDA is mandating a "boxed warning" on the drug's labeling, advising that taking the drug along with daily aspirin doses above 100 milligrams could decrease its effectiveness. The FDA is also mandating that AstraZeneca "conduct educational outreach to physicians to alert them about the risk of using higher doses of aspirin."

The boxed warning will also note that, as can happen with blood thinners generally, Brilinta may raise the odds for bleeding. According to the FDA, the most common side effects seen with Brilinta were bleeding and/or shortness of breath.

Late last month, a study presented at an American Heart Association press conference found that heart patients who took Brilinta with low-dose aspirin (less than 300 milligrams) had fewer cardiovascular complications than those taking Plavix plus low-dose aspirin. But, as the FDA noted in its approval, that benefit vanished when higher doses of aspirin were used.

Speaking at the time, Dr. Jeffrey S. Berger, assistant professor of medicine and director of cardiovascular thrombosis at NYU Langone Medical Center in New York City, said that "the study highlights that if one chooses to use ticagrelor in subjects with acute coronary syndromes, it would be logical to use aspirin 81 milligrams per day (and not 325 mg daily)."

He added that, "there is little reason to ever use aspirin 325 mg except in the acute setting of a heart attack or stroke. A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug."

More information

Find out more about preventing heart attack at the U.S. National Heart, Lung, and Blood Institute.

-- HealthDay Staff

SOURCES: U.S. Food and Drug Administration, news release, July 20, 2011; Jeffrey S. Berger, M.D., assistant professor, medicine and director, cardiovascular thrombosis, NYU Langone Medical Center, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Test That Spots Aggressive Breast Cancer
2. FDA Approves Test That Spots HER2-Positive Breast Cancers
3. FDA Approves Another New Drug to Fight Hepatitis C
4. FDA approves new drug for advanced melanoma
5. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
6. FDA Approves 1st New Lupus Drug in More Than 50 Years
7. FDA Approves First 3D Mammogram Device
8. FDA Approves First Pacemaker Deemed Safe During MRIs
9. FDA Approves First Drug to Prevent Premature Births
10. Swiss agency approves clinical trial of UCI-created neural stem cell therapy
11. ACGME board approves final duty hour and supervision standards for resident education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Blood Thinner Brilinta for Heart Patients
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... From May ... Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s technology ... independent practice growth. , “It is our priority to see practices succeed in this ...
(Date:5/6/2016)... San Diego, CA (PRWEB) , ... May 06, 2016 , ... ... of Companies, has been family-owned and operated for over 35 years. Maintaining core values ... community has driven their success and made them a leading name in San Diego ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... and David Konur, CEO of Cardiovascular Institute of the South announced today that ... performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
(Date:5/5/2016)... ... May 05, 2016 , ... Florida Hospital Pepin ... atrial fibrillation (A-Fib) an alternative to long-term warfarin medication with the newly approved ... April of 2015, Florida Hospital Pepin Heart Institute doctors successfully implanted the Watchman ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
(Date:5/4/2016)... May 4, 2016 In ... a series of free workshops across ... requirements for Good Distribution Practices (GDP). Good ... ensures that products are consistently stored, transported and handled ... (MA) or product specification. Only a few years ago, ...
Breaking Medicine Technology: